Invitation to presentation of Cantargia’s report for the second quarter of 2022 on August 30 at 3.00 p.m. CET

Cantargia AB will publish the company’s report for the second quarter for 2022 on Tuesday, August 30, 2022, at 08:30 a.m. CET.

In conjunction to the report, Cantargia invites investors, analysts, and media to an audiocast with teleconference (in English) on August 30, at 3:00 p.m. CET, where Göran Forsberg, CEO, and Bengt Jöndell, CFO, will present Cantargia and comment on the quarterly report for the second quarter 2022, followed by a Q&A-session.

The conference call can be followed at: https://tv.streamfabriken.com/cantargia-q2-2022

To attend through telephone, please dial-in at one of the numbers below:

SE: +46850558354
UK: +443333009034
US: +16467224902

The webcast will also be available on demand on Cantargia’s corporate website: www.cantargia.com

For further information, please contact:
Göran Forsberg, CEO
Telephone: +46 (0)46-275 62 60

E-mail: goran.forsberg@cantargia.com
This information was submitted for publication, through the agency of the contact person set out above, at 11.30 CET on 17 August 2022.

About Cantargia
Cantargia AB (publ), reg. no. 556791-6019, is a biotechnology company that develops antibody-based treatments for life-threatening diseases and has established a platform based on the protein IL1RAP, involved in a number of cancer forms and inflammatory diseases. The lead project, the antibody nadunolimab (CAN04), is being studied clinically in combination with chemotherapy or immune therapy in a series of clinical studies – CANFOUR, CIRIFOUR, CAPAFOUR, CESTAFOUR and TRIFOUR – with a primary focus on non-small cell lung cancer and pancreatic cancer. Positive interim data from the combination with chemotherapy indicate stronger efficacy than would be expected from chemotherapy alone. Cantargia’s second project, the antibody CAN10, blocks signaling via IL1RAP in a different manner than nadunolimab and addresses treatment of serious autoimmune/inflammatory diseases, with initial focus on systemic sclerosis and myocarditis.

Cantargia is listed on Nasdaq Stockholm (ticker: CANTA). More information about Cantargia is available at www.cantargia.com.

---